ANIX (Anixa Biosciences) ROCE % : -75.25% (As of Jan. 2025)

View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Anixa Biosciences's annualized ROCE % for the quarter that ended in Jan. 2025 was -75.25%.

Anixa Biosciences ROCE % Historical Data

The historical data trend for Anixa Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences ROCE % Chart

Anixa Biosciences Annual Data

Trend

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

ROCE %

Get a 7-Day Free Trial

-152.60

-60.74

-43.80

-42.46

-64.96

Anixa Biosciences Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
ROCE %	Get a 7-Day Free Trial															-61.16	-59.79	-65.94	-63.27	-75.25

Anixa Biosciences ROCE % Calculation

Anixa Biosciences's annualized ROCE % for the fiscal year that ended in Oct. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2024 )		(A: Oct. 2023 )		(A: Oct. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2024 )		(A: Oct. 2023 )		(A: Oct. 2024 )
	=	-13.831	/	( ( (25.522 - 2.028)	+	(21.591 - 2.5) )	/ 2 )
	=	-13.831	/	( (23.494	+	19.091)	/ 2 )
	=	-13.831	/	21.2925
	=	-64.96 %

Anixa Biosciences's ROCE % of for the quarter that ended in Jan. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2025 )		(Q: Oct. 2024 )		(Q: Jan. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2025 )		(Q: Oct. 2024 )		(Q: Jan. 2025 )
	=	-13.544	/	( ( (21.591 - 2.5)	+	(18.906 - 1.999) )	/ 2 )
	=	-13.544	/	( ( 19.091	+	16.907 )	/ 2 )
	=	-13.544	/	17.999
	=	-75.25 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2025) EBIT data.

Anixa Biosciences (NAS:ANIX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Anixa Biosciences ROCE % Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Anixa Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CY71:Germany

Address

3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118

Website

https://www.anixa.com

Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Executives

Arnold M Baskies	director	1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Titterton Lewis H Jr	director	6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Amit Kumar	director, officer: Chief Executive Officer	C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani	officer: COO & CFO	12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Emily Gottschalk	director	3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan	director
David Cavalier	director	C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams	director	C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox	director	929 NOWITA PLACE, VENICE CA 90291
Andrea Belz	director	1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender	officer: Chief Operating Officer	900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman	officer: President and CEO	C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop	officer: Sr. Vice President-Engineering	C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson	director	20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams	director	C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747